BLUE JET HEALTHCARE LIMITED
REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA,
PLOT 1 & 2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705
T : 022- 41840550 / 40037603 | F : +91 22 27814204
E : sales@bluejethealthcare.com | CIN NO. : L99999MH1968PLC014154

November 5, 2026

To,

The Manager Listing Department **BSE Limited** Phiroze Jeejebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code (BSE): 544009	The Manager Listing Department **National Stock Exchange of India Limited** Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: BLUEJET

Sub.: Outcome of Board Meeting held today i.e, Thursday, November 5, 2026.

Dear Sir / Ma'am,

In furtherance of our intimation dated October 29, 2026 and in terms with Regulation 30 read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), we hereby inform you that, the Board of Directors of the Company at their meeting held today viz. Thursday, November 5, 2026*, inter-alia,* has approved the following: -

a) Unaudited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026. A signed copy of the Unaudited Standalone Financial Results along with the Limited Review Report thereon is enclosed herewith.

The meeting commenced at 12.15 P.M. and concluded at 12. 41 P.M.

The above information will be made available on the website of the Company: www.bluejethealthcare.com

Kindly take the same on your record.

Thanking you,
Yours faithfully,

For Blue Jet Healthcare Limited

Sweta Poddar
Digitally signed by Sweta Poddar
Date: 2026.11.05 12:46:12 +05'30'

Sweta Poddar
Company Secretary & Compliance Officer
Mem. No. F12287

Independent Auditor's Review Report on unaudited financial results for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 of Blue Jet Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Blue Jet Healthcare Limited

Introduction

1. We have reviewed the accompanying statement of unaudited financial results of Blue Jet Healthcare Limited ('the Company') for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). We have initialled the Statement for identification purpose only.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.


Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS, specified under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **KKC & Associates LLP**
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621



Kamlesh Jagetia
Partner
ICAI Membership No: 139585
UDIN: 26139585JTC2MB3873
Place: Navi Mumbai
Date: 05 November 2026

BLUE JET HEALTHCARE LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THREE MONTHS AND SIX MONTHS ENDED 30-09-2026

₹ in million

	Particulars	Three Months Ended			Six Months Ended		Year Ended
		30-09-2026 (Unaudited)	30-06-2026 (Unaudited)	30-09-2025 (Unaudited)	30-09-2026 (Unaudited)	30-09-2025 (Unaudited)	31-03-2026 (Audited)
1	Revenue from Operations	3,757.44	2,931.13	1,654.81	6,688.57	5,202.39	9,473.21
2	Other Income	262.08	152.37	242.71	414.44	325.25	686.54
3	**Total Income (1+2)**	**4,019.52**	**3,083.50**	**1,897.52**	**7,103.01**	**5,527.64**	**10,159.75**
4	**Expenses**						
	Cost of Materials Consumed	2,016.36	1,788.78	1,084.24	3,805.13	2,163.14	3,881.33
	Changes [Decrease /(Increase)] in Inventories of Finished goods and Work-in-Progress	(83.01)	(417.67)	(505.58)	(500.68)	244.49	476.82
	Employee Benefits Expense	204.07	201.17	185.54	405.24	359.80	735.35
	Finance Costs	6.41	6.60	46.27	13.01	53.17	62.39
	Depreciation and Amortisation Expense	69.23	67.06	58.66	136.29	115.64	240.02
	Other Expenses	432.52	378.10	341.12	810.62	675.53	1,438.72
	Total Expenses	**2,645.58**	**2,024.04**	**1,210.25**	**4,669.61**	**3,611.77**	**6,834.63**
5	**Profit before Tax (3-4)**	**1,373.94**	**1,059.46**	**687.27**	**2,433.40**	**1,915.87**	**3,325.12**
6	Tax Expense:						
	Current Tax	331.70	265.00	179.10	596.70	477.10	812.00
	Short/ (Excess) Tax Provision related to prior years	-	-	-	-	-	0.90
	Deferred Tax (credit)/ charge	17.07	11.82	(13.19)	28.89	5.70	34.06
	Total Tax Expense	**348.77**	**276.82**	**165.91**	**625.59**	**482.80**	**846.96**
7	**Profit for the period/ year (5-6)**	**1,025.17**	**782.64**	**521.36**	**1,807.81**	**1,433.07**	**2,478.16**
8	**Other Comprehensive Income**						
	(i) Items that will not be reclassified to profit or loss	-	-	1.48	-	1.48	(2.65)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	(0.37)	-	(0.37)	0.67
	Other Comprehensive Income for the period/ year	**-**	**-**	**1.11**	**-**	**1.11**	**(1.98)**
9	**Total Comprehensive Income for the period/ year (7 + 8)**	**1,025.17**	**782.64**	**522.47**	**1,807.81**	**1,434.18**	**2,476.18**
10	Paid-up Equity Share Capital (Face Value ₹ 2 per share)	378.55	346.93	346.93	378.55	346.93	346.93
11	Other Equity						13,252.19
12	**Earnings per Share (EPS) of Face value ₹ 2/- each***						
	(a) Basic - (₹)	5.46	4.51	3.01	10.00	8.26	14.29
	(b) Diluted - (₹)	5.46	4.51	3.01	10.00	8.26	14.29
	*EPS are not annualised for interim periods						

kkc & associates llp Chartered Accountants

Blue Jet Healthcare Limited

Notes:

1 STATEMENT OF ASSETS AND LIABILITIES

₹ in million

	Particulars	As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
A.	**ASSETS**		
1	**Non Current Assets**		
	Property Plant and Equipment	2,678.51	2,529.10
	Intangible Assets	17.80	21.75
	Capital Work in Progress	3,578.68	3,013.76
	Right of Use Assets	579.60	613.43
	Financial Assets		
	Investments (Non-Current)	700.92	251.85
	Other Financial Assets	169.67	199.50
	Non-Current Tax Assets (Net)	76.51	76.51
	Other Non-Current Assets	77.80	135.25
	Total Non-Current Assets	**7,879.49**	**6,841.15**
2	**Current Assets**		
	Inventories	2,512.57	1,873.89
	Financial Assets		
	Investments (Current)	6,046.01	2,266.97
	Trade Receivables	4,446.52	3,390.46
	Cash and Cash Equivalents	767.27	608.57
	Other Balances with Banks	3,248.76	880.14
	Other Current Financial Assets	161.01	126.08
	Other Current Assets	777.15	424.32
	Total Current Assets	**17,959.29**	**9,570.43**
	TOTAL ASSETS	**25,838.78**	**16,411.58**
B.	**EQUITY AND LIABILITIES**		
1	**EQUITY**		
	Equity Share Capital	378.55	346.93
	Other Equity	22,607.38	13,252.19
	Total Equity	**22,985.93**	**13,599.12**
	LIABILITIES		
2	**Non-Current Liabilities**		
	Financial Liabilities		
	Lease Liability	334.46	375.80
	Provisions	56.52	55.79
	Deferred Tax Liabilities (Net)	135.19	106.31
	Total Non-Current Liabilities	**526.17**	**537.90**
3	**Current Liabilities**		
	Financial Liabilities		
	Lease Liability	51.03	46.04
	Trade Payables		
	Total outstanding dues of Micro, Small and Medium Enterprises	76.03	62.23
	Total outstanding dues to other than Micro, Small and Medium enterprises.	400.16	506.97
	Other Current Financial Liabilities	466.90	495.48
	Current Tax Liabilities (Net)	1,256.59	1,119.26
	Other Current Liabilities	39.80	19.95
	Provisions	36.17	24.63
	Total Current Liabilities	**2,326.68**	**2,274.56**
	TOTAL EQUITY AND LIABILITIES	**25,838.78**	**16,411.58**

KKC & Associates LLP Chartered Accountants

Blue Jet Healthcare Limited

2 STATEMENT OF CASH FLOWS

₹ in million

	Particulars	Six months ended 30-09-2026 (Unaudited)	Six months ended 30-09-2025 (Unaudited)
A.	**Cash Flow from Operating Activities:**		
	Profit Before tax	2,433.40	1,915.87
	Adjustments for:		
	Depreciation and Amortisation	136.29	115.64
	(Gain)/Loss on Fair Valuation of Investments	(95.47)	(40.69)
	Provision for Employee Benefits	13.65	15.43
	(Reversal of)/Provision for Bad Debts/ Bad debts Written off	4.80	0.43
	Interest Income	(87.41)	(43.86)
	Preference Dividend	0.01	0.01
	Finance Costs	13.00	53.16
	Unrealised Foreign Exchange (Gain) / Loss	(83.01)	(60.46)
	Amortization of Deferred Lease Expense	0.46	0.21
	(Profit) / Loss on Sale / Retirement of Property, Plant and Equipment (net)	(0.97)	-
	Profit on Sale of Investments (net)	(22.86)	(44.25)
	Operating profit before working capital changes	**2,311.89**	**1,911.49**
	Movements in working capital:		
	Increase/ (Decrease) in Trade payables and other Liabilities	(115.97)	(433.81)
	(Increase)/ Decrease in Trade receivables	(964.53)	483.44
	(Increase)/ Decrease in Inventories	(638.68)	671.34
	(Increase)/ Decrease in Financial and Other Assets	(389.45)	(35.79)
	Cash generated from Operations	**(2,108.63)**	**685.18**
	Taxes paid (net of refunds)	(459.38)	(524.80)
	Net Cash generated from/ used in Operating Activities (A)	**(256.12)**	**2,071.87**
B	**Cash Flow from Investing Activities:**		
	Purchase of Property, Plant and Equipment and Intangible Assets	(761.39)	(1,254.65)
	Sale of Property, Plant and Equipment	3.72	-
	Redemption/ (Investment) in Fixed Deposits (net)	(2,287.36)	(282.50)
	Purchase of Investments	(6,727.88)	(3,060.05)
	Sale of Investments	2,618.10	2,907.96
	Interest received	39.97	42.92
	Net Cash used in Investing Activities (B)	**(7,114.84)**	**(1,646.32)**
C	**Cash Flow from Financing Activities:**		
	Repayment of Principal towards Lease Liability	(36.35)	(32.20)
	Interest Paid on Lease Liability	(13.00)	(6.24)
	Proceeds from issue of equity Shares through Qualified Institutional Placement (QIP)	8,000.00	-
	Share issue expenses	(193.87)	-
	Equity Dividend Paid	(227.13)	-
	Interest Paid on current borrowings	-	(46.92)
	Net Cash generated from/ used in Financing Activities (C)	**7,529.65**	**(85.36)**
	Net Increase/ (Decrease) in Cash and Cash Equivalents (A + B + C)	158.70	340.19
	Cash and Cash Equivalents at the beginning of the year	608.57	329.79
	Cash and Cash Equivalents at the end of the year	**767.27**	**669.98**

kkc & associates llp Chartered Accountants

Blue Jet Healthcare Limited

3 The above financial results of the Company for the three months and six months ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 05, 2026. Further, the above financial results have been reviewed by the Statutory Auditor of the Company.

4 The company is engaged in manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products and the same constitutes a single reportable business segment as per IND AS 108.

5 During the quarter ended September 30, 2026, the Company allotted 1,58,10,276 equity shares of face value of ₹ 2 each to the eligible Qualified Institutional Buyers (QIB), at the issue price of ₹ 506 per equity share (including a premium of ₹ 504 per equity share), aggregating to ₹ 8,000.00 million, pursuant to Qualified Institutional Placement (QIP) in accordance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations (the "SEBI ICDR Regulations").

6 The Company does not have any subsidiaries, associates, or joint ventures as on September 30, 2026. Consequently, the preparation of consolidated financial statements is not applicable.

For and on behalf of Board of Directors

Navi Mumbai
Date: November 05, 2026

Shiven Arora
Managing Director

kkc & associates llp
AB
Chartered Accountants

Blue Jet Healthcare Limited